SEBI imposes fine on Biocon's regulatory affair officer for insider trading
Mumbai: In a major setback to Biocon Ltd., markets regulator Securities and Exchange Board of India (SEBI)on Friday levied a fine on an employee attached to the drugmaker for violating insider trading norms while dealing in the scrip of the firm.
As per a recent PTI report, the employee, V. Singh (noticee), general manager regulatory affair of Biocon at the time of investigation and also a designated person, is facing a fine of Rs 3 lakh for violating provisions of Prohibition of Insider Trading (PIT) norms.
An investigation carried out by the regulator found that Singh, who held 9,550 shares of the company, acquired through exercise of employee stock option plan (ESOP), sold 3,550 shares between May 2018 to September 2018 without seeking pre-clearance from the compliance officer.
"The noticee by not obtaining pre-clearance from the compliance officer of Biocon for the transactions in question has violated the provisions of PIT Regulations," Sebi stated.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.